Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Authors:
Open Access
- 1 May 2010
- journal article
- practice guideline
- Published by Elsevier in Annals of Oncology
- Vol. 21 (suppl_5) , v228-v231
Abstract
Cancers of unknown primary site (CUPs) represent a heterogeneous group of metastatic tumours for which a standardized diagnostic work-up fails to identify the site of origin at the time of diagnosis. CUPs account for 3%–5% of all malignancies. The unique biology of these tumours remains unknown. Nonetheless current data suggest that metastatic dissemination can occur in the absence of a primary tumour growth by virtue of inherent metastatic aggressiveness of cancer cells or through site-specific transformation of circulating cells, by oncogene induction at metastatic stoma.Keywords
This publication has 19 references indexed in Scilit:
- Molecular assignment of tissue of origin in cancer of unknown primary may not predict response to therapy or outcome: A systematic literature reviewCancer Treatment Reviews, 2009
- Parallel progression of primary tumours and metastasesNature Reviews Cancer, 2009
- Pathologic Evaluation of Unknown Primary CancerSeminars in Oncology, 2009
- Seeding and Propagation of Untransformed Mouse Mammary Cells in the LungScience, 2008
- Switching benchmarks in cancer of unknown primary: From autopsy to microarrayEuropean Journal of Cancer, 2007
- Cancer of Unknown Primary Site: Missing Primary or Missing Biology?The Oncologist, 2007
- Diagnostic and therapeutic management of cancer of an unknown primaryEuropean Journal of Cancer, 2003
- Summary of the Standards, Options and Recommendations for the management of patients with carcinoma of unknown primary site (2002)British Journal of Cancer, 2003
- Development and Validation of a Prognostic Model to Predict the Length of Survival in Patients With Carcinomas of an Unknown Primary SiteJournal of Clinical Oncology, 2002
- Analysis of a diagnostic strategy for patients with suspected tumors of unknown origin.Journal of Clinical Oncology, 1995